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AbstrACt
Introduction A recently recognised form of chronic 
kidney disease (CKD) of unknown origin (CKDu) 
is afflicting communities, mostly in rural areas in 
several regions of the world. Prevalence studies are 
being conducted in a number of countries, using a 
standardised protocol, to estimate the distribution of 
estimated glomerular filtration rate (eGFR), and thus 
identify communities with a high prevalence of reduced 
glomerular filtration rate (GFR). In this paper, we 
propose a standardised minimum protocol for cohort 
studies in high-risk communities aimed at investigating 
the incidence of, and risk factors for, early kidney 
dysfunction.
Methods and analysis This generic cohort protocol 
provides the information to establish a prospective 
population-based cohort study in low-income settings 
with a high prevalence of CKDu. This involves a baseline 
survey that included key elements from the DEGREE 
survey (eg, using the previously published DEGREE 
methodology) of a population-representative sample, 
and subsequent follow-up visits in young adults 
(without a pre-existing diagnosis of CKD (eGFR<60 
mL/min/1.73m2), proteinuria or risk factors for CKD 
at baseline) over several years. Each visit involves 
a core questionnaire, and collection and storage of 
biological samples. Local capacity to measure serum 
creatinine will be required so that immediate feedback 
on kidney function can be provided to participants. After 
completion of follow-up, repeat measures of creatinine 
should be conducted in a central laboratory, using 
reference standards traceable to isotope dilution mass 
spectrometry (IDMS) quality control material to quantify 
the main outcome of eGFR decline over time, alongside 
a description of the early evolution of disease and risk 
factors for eGFR decline.
Ethics and dissemination Ethical approval will be 
obtained by local researchers, and participants will 
provide informed consent before the study commences. 
Participants will typically receive feedback and advice 
on their laboratory results, and referral to a local health 
system where appropriate.
IntroduCtIon
A mysterious form of chronic kidney 
disease (CKD) is afflicting young adults, 
mostly in rural communities in a number of 
low-income and middle-income countries 
(LMICs).1–10 This disease has been termed 
CKD of undetermined cause (CKDu). 
Several definitions for CKDu exist; the 
criteria typically include demonstration 
of renal damage using biomarkers in the 
absence of diabetes, severe hypertension or 
evidence of alternative renal diagnoses.11–14 
This syndrome has caused thousands of 
deaths and reduced the life expectancy 
among young adults in Mesoamerica, South 
Asia and possibly in other tropical/subtrop-
ical regions of the world.7 15–19 The cause(s) 
strengths and limitations of this study
 ► We propose a prospective generic cohort protocol 
for populations affected by chronic kidney disease 
of unknown origin in which the sampling frame 
consists of the entire at-risk population. In addition, 
the use of this standardised protocol will allow for 
regional and international comparisons.
 ► Serial estimated glomerular filtration rate measure-
ments in an apparently healthy population will al-
low the description of the evolution of disease and 
reduce problems associated with recall bias and 
reverse causation when assessing potential risk 
factors.
 ► Samples will be analysed in a single batch at the 
end of the study to minimise time-dependent mea-
surement errors.
 ► A biobank is expected to be created in each centre 
to store biological samples for future analyses.
 ► As for any cohort, loss to follow-up could pose a 
threat to validity of the study, and every effort must 
be made to mitigate this.
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of CKDu are not yet established, but proposed aetiol-
ogies include recurrent dehydration/heat stress, pesti-
cides, infections and heavy metals.1 20–22 In addition, 
there is no evidence that these forms of CKDu have a 
unified causality or are due to different aetiologies in 
diverse parts of the world.
Although a broad range of cross-sectional studies 
investigating prevalence of CKDu have been conducted 
in Mesoamerica, South Asia and other regions of the 
world,1–7 9 17 these have generally not used standardised 
methodology, and therefore do not allow for valid inter-
national comparisons. A recently published standardised 
protocol (the Disadvantaged Populations eGFR Epide-
miology Study (DEGREE) protocol) for estimating the 
population distribution of glomerular filtration rate 
(eGFR) has addressed this concern, and is being used 
in communities suspected to have a high prevalence of 
reduced eGFR. The DEGREE protocol makes it possible 
to undertake comparisons internationally, by mandating 
a population-representative sample and standardised 
collection of information on sociodemographic factors, 
occupational and environmental exposures, body compo-
sition and kidney function.23 To date, studies using the 
DEGREE methodology have been conducted in four 
countries (Peru, Sri Lanka, India and Malawi), with a 
number of future projects in preparation or in progress.17
A recent meta-analysis highlighted the lack of robust 
studies that have considered risk factors for early kidney 
damage in CKDu.24 This is of key importance as those 
with even apparently mildly damaged kidneys (eg, a 
borderline elevated serum creatinine (sCr) but no renal 
reserve) may experience progressive renal decline in 
response to a wide range of exacerbating insults (eg, 
episodes of dehydration/heat stress, nephrotoxic medi-
cation or other nephrotoxic exposures) making identi-
fication of causal associations challenging in those with 
existing kidney damage. Based on our experience,25 26 
we propose a generic cohort protocol to characterise the 
decline in kidney function over time and conduct aetio-
logical research in those without pre-existing CKD/risk 
factors at baseline but at risk of CKDu. Our focus is on 
conducting such cohort studies in populations that are 
at high risk for CKDu, that is, that have previously been 
classified as such by surveys based on cross-sectional eGFR 
measurements. In general, this work would follow on 
from a study using the DEGREE protocol, and hence we 
will use the term ‘CO-DEGREE’ (cohorts based on the 
DEGREE study) for such studies. Indeed, in some situ-
ations, a DEGREE survey may form the ‘baseline’, with 
a subgroup of DEGREE survey participants then being 
selected for follow-up based on age, a single measure-
ment of eGFR ≥60 mL/min/1.73 m2 (accepting that this 
is likely a conservative cut-off for pre-existing kidney 
dysfunction) and without clinical diagnosis or history of 
hypertension, diabetes mellitus, obesity or other known 
risk factor that could potentially explain CKD. However, 
the standardised protocol we propose here can also be 
used as a ‘stand-alone’ study design in any well-defined 
study group, without requiring that a DEGREE survey is 
conducted first.
We are already conducting such a cohort study in Nica-
ragua,25 26 and have had many challenges to address, 
including (1) community engagement, awareness of 
conditions, political unrest and ethics; (2) follow-up over 
time (frequency and minimising loss to follow-up); (3) 
fieldwork and laboratory standards to ensure decline is 
detected and (4) regular feedback information on study 
progress. We will draw on our experience in Nicaragua 
in presenting both the generic CO-DEGREE protocol 
and observations on the practical issues involved in 
conducting such studies in a particular population.
objECtIvEs
Studies using this generic cohort protocol, and contrib-
uting to the wider DEGREE collaboration, will aim to
1. Investigate the evolution of, and risk factors for, kidney 
function decline over time among populations at risk 
of CKDu.
2. Compare the evolution, and risk factors for kidney 
function decline, in different populations and regions 
at risk of CKDu.
3. Establish a framework for international collaboration 
and promote a network for future work on the causal-
ity of CKDu.
rationale for a cohort study of decline in eGFr
A representative sample of those at risk
Population-based cohort studies have several advan-
tages:27 first, this type of study allows the recruitment 
of a representative sample of the at-risk population, for 
example, it will include workers from a variety of occu-
pations (including unemployed) at the community level. 
Assuming that the study sample is randomly selected 
from the entire at-risk population based on a commu-
nity census, and there are no substantial problems with 
non-response, these studies are unlikely to be affected 
by significant selection bias. Furthermore, in contrast 
to studies conducted solely in an occupational setting, 
differential loss to follow-up is likely to be less prob-
lematic, particularly if workers are screened for kidney 
disease within that setting and potentially denied further 
work.
Like all prospective cohort studies, to ensure the entire 
population is ‘at risk’, those with the outcome at baseline 
should be excluded, although it is recognised that inves-
tigators may wish to follow up those with eGFR <60 mL/
min/1.73 m2 and those with established risk factors for 
CKD for other purposes (see below).
One general disadvantage of population-based studies 
is that this approach typically requires large sample sizes 
and long-term follow-up if disease is not highly prevalent. 
However, the focus of CO-DEGREE is on conducting 
studies in population with a high prevalence of CKDu 
(see below).25 27
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Figure 1 Flowchart and study procedures of CO-DEGREE protocol.
Handling reverse causation and recall bias
The problem of reverse causation (eg, modification of 
behaviour or work tasks in response to the diagnosis of 
renal impairment) can be minimised in a cohort study by 
focusing on people without pre-existing disease, and then 
following these initially apparently ‘healthy’ participants 
over time. Similarly, a cohort approach, unlike cross-sec-
tional studies, is less prone to recall bias regarding 
previous exposures.
Measuring kidney function
Quantification of kidney function is most easily under-
taken by determining sCr concentration, which is rela-
tively easy and cheap to measure, and then calculating 
the eGFR. A case of CKDu is typically defined by an eGFR 
<60 mL/min/1.73 m2 (sustained for at least 3 months to 
confirm chronicity) in the absence of known causes of 
kidney disease. However, this dichotomous definition has 
weaknesses in studies exploring the causation of CKDu, 
as it is well established that substantial damage may have 
already occurred at the histological level before serum 
biomarkers of renal dysfunction become abnormal (and 
other markers such as proteinuria are often absent in this 
disease). Furthermore, repeat measures after 3 months 
are not always performed in cross-sectional surveys, and 
sCr levels are modified by multiple non-renal factors 
such as high animal protein intake, strenuous exercise, 
changes in plasma volume, body mass index, sex, age, 
ethnicity and some drugs28; thus, cross-sectional studies 
examining associations with reduced eGFR based on a 
single sCr measurement may be prone to a significant 
degree of misclassification, especially in smaller studies. 
Notably, the accuracy of sCr determinations is also an 
inherent problem (see further below). In addition, the 
Chronic Kidney Disease Epidemiology Collaboration 
(CKD-EPI) or The Modification of Diet in Renal Disease 
Study (MDRD) equations used to calculate eGFR from 
sCr28 have not been validated in many populations 
reported to be suffering CKDu,29 potentially further 
increasing misclassification bias in cross-sectional studies.
Alternative approaches based on serial eGFR measure-
ments in the same person over time render between-person 
variation less problematic. If estimated across a period of 
time using multiple measures with sustained preanalytical 
and analytical quality, this will also reduce the influence 
of the within-person factors that are not directly related 
to kidney damage. In summary, an approach using serial 
eGFR measures substantially improves the potential to 
identify risk/causal factors for CKDu as well as allowing 
the description of the evolution of disease.
CorE protoCol
study design
This is a prospective cohort study protocol for studying 
decline in kidney function over time in populations 
with high reported prevalence of CKDu, primarily in 
LMICs. We consider the following study design issues: 
(1) population sampling strategy and follow-up interval, 
(2) questionnaire development and delivery, (3) clinical 
measurements and biosampling and (4) data manage-
ment and reporting25 (see figure 1). In addition, we 
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Table 1 Sample size calculations
Parameters Scenario 1 Scenario 2 Scenario 3 Scenario 4 Scenario 5 Scenario 6 Scenario 7 Scenario 8
Population frequency of 
eGFR decline
0.04 0.06 0.08 0.10 0.04 0.06 0.08 0.10
Proportion population 
exposed
0.5
OR associated with 
exposure
2 3
P (outcome|unexposed) 0.027 0.04 0.053 0.066 0.02 0.03 0.04 0.05
P (outcome|exposed) 0.054 0.08 0.106 0.132 0.06 0.09 0.12 0.15
Group size 993 686 405 436 463 317 243 200
Sample size 1986 1372 810 872 926 634 486 400
Calculations based on equal proportion of the population exposed/unexposed for simplicity. No adjustments made for loss to follow-up or 
multiple testing.
P indicates probability, assumes 1-β=0.80; =0.05.
eGFR, estimated glomerular filtration rate.
discuss (1) sample size and follow-up duration and (2) 
ethical considerations.
population, sampling strategy and follow-up interval
In Mesoamerica, CKDu typically affects young men on the 
Pacific Coast. This population is dying in their 40s, often 
younger, from end-stage renal disease.15 30 The disease 
appears to occur at a later age in South Asia, with few 
cases occurring in men in their 20s.7 31 Nevertheless, one 
might expect preliminary changes in GFR to occur early 
in adulthood. In general, the study population should 
include participants who are old enough to experience 
an identifiable decline in kidney function, but not older 
age groups (eg, >60 years old) where the prevalence of 
CKD is already high in many populations globally (eg, up 
to 10%). Thus, inclusion criteria should be tailored to 
the local disease profile, but the default approach should 
be to recruit participants aged 18–40 years old (though 
18–30 might be more appropriate in Central America, 
and 18–50 may be more appropriate in areas such as 
South Asia where age of onset appears older). The ratio-
nale for including people ≥18 years old was based on 
definition on adult life, and may be lowered, especially 
in populations where the working life starts years earlier. 
A population-census should be conducted to identify 
all potential participants in the appropriate age range 
and either the entire population recruited, or a random 
sample selected. In either case, response rates by age and 
sex should be reported.
The focus of these studies is to conduct aetiological 
research in those without traditional CKD/risk factors at 
baseline; thus, the sample size estimates (see below) are 
based on following a cohort in which those with evidence 
of pre-existing CKD, diabetes or hypertension have been 
excluded.25 Diabetes can be diagnosed by self-report, 
use of medication or lab tests (fasting serum glucose: 
≥7.0 mmol/L or HbA1C ≥48 mmol/mol),32 33 and hyper-
tension by self-report, use of medication or measurement 
(seated, average BP ≥140/90 mmHg on second and third 
of three readings).34
In addition to self-report of CKD, those with previously 
detected eGFR <60 mL/min/1.73 m2, proteinuria (eg, 
albumin/creatinine ratio (ACR) >300 mg/g or dipstick 
3+ or greater)35 on testing at baseline should be excluded 
from the study. It is recognised that a proportion of partic-
ipants not excluded by these criteria may still have some 
form of underlying kidney abnormality (eg, low-level 
proteinuria), and some of those excluded due to a low 
eGFR at baseline may go on to recover function, but this 
represents a pragmatic approach to excluding those with 
significant pre-existing renal disease at baseline. Further-
more, for practical, ethical or scientific reasons (eg, to 
gain insight into progression of established CKDu or 
other non-communicable disease research aims), investi-
gators may wish to study an entire population (including 
those with pre-existing clinical diagnosis of, or newly 
identified, CKD, diabetes mellitus and hypertension), 
but in that case, it is important to ensure that there are 
sufficient ‘disease-free’ participants included at base-
line to meet the sample size requirements (see table 1). 
Although the disease is generally more common in men, 
women with CKDu are of strong scientific interest in that 
they may suggest alternative risk factors, or help to rule 
out some that have been previously proposed. Hence, 
recruitment should in general involve equal numbers of 
men and women, though women who are pregnant at 
recruitment are also excluded, since pregnancy-related 
changes in eGFR are challenging to interpret.
The baseline study visit will require the administration 
of the core questionnaire, with additional context-spe-
cific additions, clinical measurements and biological 
samples. Subsequent to the baseline visit, follow-up visits 
should be conducted at least annually for a minimum 
follow-up of 2 years to evaluate the study outcome and 
keep close contact with the participants and update their 
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Table 2 Details and procedures of the baseline study visit and subsequence follow-up
Items
Baseline visit
(0 month)
Follow-up period
(variable)
12 months 24 months 36 months 48 months
At 
completion
Community census X – – – – –
Participants enrolment X – – – – –
Informed consent X           
Update personnel contact information X X X X X   
Anthropometric measurements X X X X X   
Biological samples X X X X X   
Baseline core questionnaire X – – – –   
Follow-up questionnaire   X X X X   
Local serum creatinine measurement X X X X X   
Results feedback X X X X X   
Biobank X X X X X   
Batch testing of serum creatinine           X
contact information. This will help minimise the loss to 
follow-up at each study point. Substantial seasonal varia-
tion in eGFR has been reported in a number of settings 
(both CKDu related and unrelated).26 36–38 Therefore, the 
conduct of additional study visits at a 6-monthly interval 
(eg, at beginning and end of summer season) might be 
useful in explaining within-person eGFR variation as well 
as providing important information for the wider popu-
lation on the significance of kidney function testing at 
different time points in the year (perhaps for a subset of 
participants or a proportion of the follow-up period) (see 
table 2).
Questionnaires
The purpose of the baseline core questionnaire is to 
obtain a minimum dataset to explore associations with 
decline in kidney function and make comparisons within 
and between persons. The baseline core questionnaire 
(online supplementary file 1) is based on the question-
naire used in the DEGREE protocol and has been used 
in DEGREE-related studies in a number of settings. The 
baseline core questionnaire represents a minimum dataset 
and it will provide basic information on exposures such 
as sociodemographic factors, occupational and environ-
mental exposure, lifestyle, diagnosis of infectious diseases 
and medication. Local research teams may decide to add 
data items of specific interest to the core dataset, partic-
ularly items of relevance to societal and occupational 
context and/or environmental samples. They also have 
the responsibility to translate, validate and to make any 
local contextual changes. Training procedures for the 
field staff should be documented.
Researchers will return to field (at least) annually for 
in-person follow-up visits. At these follow-up visits, partici-
pants are invited to respond to a follow-up questionnaire 
(online supplementary file 2), provide biosamples and 
update their contact information.
Clinical measurements
Blood pressure and heart rate should be measured on the 
right arm after 5 min rest in the sitting position using an 
automated sphygmomanometer, WHO validated for the 
clinical setting (eg, Omron HEM-907XL sphygmoma-
nometer), and the average of the first, second and third 
of three readings is recorded. Subjects height and weight 
(in meters and kilograms) should be measured (without 
shoes) using a stadiometer and digital calibrated scales.
biosamples
Fasting blood and urine samples will be collected at each 
study visit and stored in the field into coolers with icebox 
(4°C) no more than 4 hours before processing.
Dipstick urinalysis should be performed by using elec-
tronic readers (urine chemistry analyser) where possible, 
or otherwise at least 10% of tests should be re-analysed by 
a second investigator. Parameters that should be reported 
are urinary specific gravity, pH, protein, blood, leuco-
cytes, nitrite, glucose, etcetera. Investigators with access 
to ACR measurements may wish to perform these assays 
(at least at baseline and annually).
Samples for serum analysis should be centrifuged at 
3500 rpm for 10 min within 4 hours of collection, and 
subsequently separated into at least four aliquots of 
1–2 mL and stored at ≤−20°C (ideally −80°C). One aliquot 
should be used for contemporary sCr measurements, 
for example, by using the modified Jaffe assay (ideally 
also using standards traceable to isotope dilution mass 
spectrometry (IDMS) reference material). At baseline 
and during each study visit, a cross-checking of local lab 
quality control is highly recommended to ensure that sCr 
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determinations are comparable as these lab results may 
guide referral to clinical care for participants during the 
follow-up period. A further aliquot should be stored for a 
repeat batch measurement of sCr in all samples (a subset 
of samples from each study visit will be adequate if IDMS 
referenced methods are used on initial measurement) at 
the end of follow-up using a method traceable to an IDMS 
reference material (and potentially also cystatin C).
The CO-DEGREE group suggests the storage of at least 
a further two 1–2 mL aliquots of serum and a similar 
amount of urine in addition to those described above. 
Additional samples and analyses should be pursued 
depending on the priorities of the local research team. 
All samples for future analysis should be stored at ≤−20°C 
(ideally −80°C) in a local or international biobank. Such 
a biobank requires an uninterruptible power supply to 
protect the samples.
Investigators should assess (as part of their public 
engagement efforts) and, if appropriate, obtain consent 
from participants for future use of samples for further 
(specific and/or more general) use both locally and 
internationally (eg, through the DEGREE collaboration) 
as well as ensure that storage capacity is available.
data management and reporting
Questionnaires and samples will be labelled using a 
unique bar-code to maintain participant confidentiality. 
Electronic data capture systems such as Open Data Kit39 
may be the most resource efficient method to capture 
questionnaire data but where hard copies are used, 
double data-entry should be undertaken to minimise the 
transcription errors.
The CO-DEGREE protocols are openly available to 
interested research teams. Although primarily designed 
to be used in population-based studies, similar approaches 
could also be used in an occupational or other selected 
cohorts.
Each centre will be the ‘owner’ of their data and 
expected to publish the results of their study inde-
pendently. However, where a study is registered as part of 
the DEGREE collaboration, the coordinating centre will 
request a digital copy of anonymised individual-level data 
to allow the undertaking of international comparisons. In 
addition, a summary of local contextual information and 
a description of the population characteristics along with 
response rates will be requested. The importance of such 
information is emphasised.
sample size and follow-up duration
The overall size of the cohort will be largely dependent 
on the proportion of the ‘healthy’ population which is 
expected to experience a ‘substantial’ decline in eGFR 
over time in the community as a result of CKDu. As 
discussed above, demonstrating that reduced renal func-
tion without diabetes, hypertension or known kidney 
diseases is prevalent on a cross-sectional basis is a neces-
sary first step before pursuing this work. If, for example, 
this study protocol was to be conducted in a general 
population sample in Europe or the USA with similar 
exclusion criteria, there would be very little or no decline 
of kidney function in the young adult population. In 
contrast, in our Nicaragua study of apparently healthy 
adults aged 18–30 years,25 26 there was a clearly distinct 
subgroup which experienced a marked decline in kidney 
function over a short time, whereas the eGFR in the other 
study participants was relatively stable. Given this distri-
bution of such eGFR trajectories in the population, we 
would expect any analysis of risk factors to be conducted 
using a prospective case-control approach.
Therefore, the sample size requirements to detect an 
association with an exposure at any given power will be 
determined by the following factors:
1. Proportion of the population that experience ‘substan-
tial’ decline. In turn the power to detect ‘substantial’ 
decline will depend on the following:
a. The rate of eGFR decline in those affected.
b. The duration of follow-up.
c. The number of eGFR measures.
2. Proportion of general population exposed to any ex-
posure of interest.
3. Effect size of any exposure.
4. The study retention rate.
Taking a simplistic approach, the duration of the study 
should be designed so that those affected have sustained a 
clinically important loss of kidney function, for example, 
20% of normal eGFR. Therefore, if CKDu in the study 
population is predicted, from a baseline of ≥60 mL/min 
eGFR, to lead to a loss of eGFR of a magnitude of 5% 
each year (~7 mL/min/1.73 m2/year), the study dura-
tion should be 4 years. If, alternatively, loss is predicted 
to be 10% each year, study duration could be as short as 
2 years. Additional eGFR measures, over and above the 
suggested annual frequency, will reduce error associated 
with determining trajectory (and might be performed for 
the reasons discussed above) but either way a minimum 
follow-up of 2 years is recommended.
After basing the study duration on the expected rate of 
eGFR decline among those affected, the sample size can 
then be calculated on the basis of the expected frequency 
of ‘substantial’ decline among the population and the 
effect size of any proposed exposure that it is desirable 
to detect. A number of scenarios are outlined in table 1. 
A further (eg, 20%, depending on local circumstances) 
increase in target recruitment is advised to allow for loss 
to follow-up.
Finally, these initial sample sizes will need adjustment 
for exclusions based on estimates of the prevalence of 
previously unknown CKD (based on eGFR/albuminuria 
tests), diabetes, hypertension or other known causes of 
CKD at baseline (unless these data are already available 
from a previously conducted cross-sectional study). It is 
worth considering whether people who may have CKD 
(or CKD risk factors) will be aware of this, as this may 
affect the numbers of participants that will be retained 
for the analysis following testing. For example, if there 
is screening for kidney problems (as in some Central 
Tropical M
edicine. Protected by copyright.
 o
n
 O
ctober 4, 2019 at London School of Hygiene and
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-031169 on 24 September 2019. Downloaded from 
7Gonzalez-Quiroz M, et al. BMJ Open 2019;9:e031169. doi:10.1136/bmjopen-2019-031169
Open access
American Sugarcane mills or community-based screening 
in Sri Lanka), then potential cohort participants may be 
aware of their kidney function status and can be excluded 
from the study sample prior to recruitment. For example, 
5% of the target population in the community studied in 
Nicaragua reported pre-existing CKD. Nevertheless, there 
was an additional 10% who had undiagnosed impaired 
kidney function at baseline assessment based on their 
laboratory findings, highlighting the importance of iden-
tifying an age group where CKDu is not already highly 
prevalent so as to satisfy a key inclusion criterion (absence 
of CKD at baseline) when calculating sample sizes.
Ethics and dissemination
Local research teams will ensure these studies are 
conducted in accordance with the Declaration of Helsinki 
Principles and be responsible for assuring that the work is 
approved by the local institutional review board. Written 
informed consent will be obtained from all participants 
before taking part in the study. Information should be 
transparent in terms of using the data and biosamples 
stored for future research. Typically, a key aspect of the 
ethical review of any protocol is a discussion surrounding 
the provision of feedback and advice to participants when 
abnormal results become available. In most settings, these 
processes should be developed in partnership with local 
communities. Furthermore, mechanisms will need to be 
established in collaboration with local health providers/
healthcare systems to define pathways for participants 
needing referral for medical care. Findings from these 
studies should be disseminated widely by publication in 
peer-reviewed journals and presentations/representa-
tions to relevant local stake holders.
patient and public involvement
Patients or member of the public were not involved in 
the design of this protocol. Procedures will vary by loca-
tion; however, the DEGREE Steering Committee would 
encourage active involvement of lay members of study 
communities in additional design elements and imple-
mentation of these studies, particularly relating to the 
ethical issues above. For example, it is expected that study 
participants will receive the results of their lab tests, expla-
nations of them and a reference to the relevant health 
centre, if appropriate. However, the best mechanisms for 
doing this will vary by location.
Experience with the Co-dEGrEE protocol in nicaragua
The protocol presented here is, by necessity, generic. The 
approaches and challenges of implementing the protocol 
will vary widely in different populations and regions of 
the world. However, since we have already implemented 
this protocol in a study in Nicaragua,25 26 we will make 
some observations on the practicalities, and challenges, 
or implementing the protocol in this context.
The Nicaragua study involved community-based 
follow-up in Leon and Chinandega departments.25 A 
number of strategies were used to maximise response 
and retention rates. As the workday starts very early in the 
morning and finishes late in the afternoon, attempts were 
made to conduct data collection during economically less 
active (eg, each side of the main sugar harvest) periods 
of the year, so as to still capture approximately 30% of 
participants who were employed at the time. Addition-
ally, participants receive their kidney test results within a 
fortnight of the study visits and receive reimbursement 
of expenses and any lost income they have incurred to 
attend the study visit. Although study visits have been time-
tabled to occur outside of the harvest season, employees 
still express the concern that their employment opportu-
nities might be affected by taking part in the study. In an 
attempt to mitigate against these types of consequences, 
the study team have corresponded with local employers 
explaining the content and extent of this study in order 
to reduce any concerns about workers’ participation. In 
addition, the study team takes particular precautions to 
maintain participant’s confidentiality during the study 
and beyond.
Conducting a follow-up study in a rural area remains 
a major challenge. Alongside the logistical challenges 
of reaching geographically isolated neighbourhoods 
along poor-quality roads, a significant obstacle has been 
internal and external migration due to lack of employ-
ment source or social unrest. Rural communities have a 
tradition of working with seasonal crops, and sugarcane 
workers often leave their communities at the end of each 
harvest season, to go abroad or to other regions within 
the country in search of temporary employment. In our 
study, at the end of each harvest, up to 30% of the study 
population had left their communities in search of alter-
native employment during the non-harvest period in 
our study. Despite these problems, our team achieved 
attendance at 92% of all scheduled visits over 2 years.25 26 
However, the level of investment of time and resources 
should not be underestimated.
Finally, continuing community engagement and the 
maintenance of good relationships between researchers, 
community leaders, participants and communication with 
local healthcare system have been key. The development 
of standardised procedures for use by the research team 
may be useful in this context, for example, a reference 
flowchart for communication with local health posts/
primary hospital or hospital for persons with health prob-
lems detected during the study.
dIsCussIon
The CO-DEGREE protocol was developed in response 
to the highly prevalent form of CKD of unknown cause 
that is affecting Mesoamerica and other countries around 
the globe. To date, the existing epidemiological studies 
of CKDu have provided an incomplete understanding of 
the evolution of and risk factors for disease. This CO-DE-
GREE protocol aims to provide a framework to address 
this.
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This CO-DEGREE protocol is designed to capture the 
entire at-risk population by aiming to recruit men and 
women, and those who work across a variety of different 
occupations. The main outcome measure of within-person 
loss of eGFR over time, which means it should be possible 
to capture the earliest stages of disease, making associ-
ations with possible causal exposures (and exacerbating 
factors) less prone to reverse causation and recall bias.
We do not underestimate the challenges posed by the 
lack of language-validated and standardised exposure 
questionnaires in this area. The accompanying question-
naire represents a minimum, and most studies will use an 
expanded dataset. Currently, there is an absence of glob-
ally generalisable instrument to capture environmental 
and occupational exposures; however, the DEGREE 
group is undertaking further work in this area. Addition-
ally, short-term or long-term environmental measure-
ments and/or novel biomarkers that capture exposure 
to heat, agrichemicals and/or infection in either the 
community or workplace are likely to be valuable addi-
tions to this type of study but are beyond the scope of this 
basic protocol.
Finally, it should be emphasised that this protocol is not 
suitable for studying the progression of CKD in general, 
due to the specific constraints introduced by excluding 
those with hypertension, diabetes and CKD as well as 
other known causes of CKD (ie, those with proteinuria 
and/or with reduced eGFR) at baseline. Indeed, in 
settings where there is not a high prevalence of CKDu, a 
cohort comprising people without traditional risk factors 
for CKD or with CKD would be unlikely to identify any 
detectable kidney function loss over time in the young–
adult population. For studies outside the CKDu arena, 
investigators are advised to use alternative methodolo-
gies using established protocols, for example, the CRIC 
study.40
In conclusion, we have designed a CO-DEGREE 
protocol that can be used in the different settings around 
the globe to investigate the evolution of CKDu and the 
associated risk factors for decline in kidney function. 
These studies should provide important information 
on the early decline in kidney function across different 
affected areas as well as key insight into the cause(s) of 
disease.
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